Semaglutide, also known as Ozempic and Wegovy, is a medication developed by Novo Nordisk for the treatment of type 2 diabetes and obesity. The patent for semaglutide is expected to expire in 2035, according to DrugPatentWatch.com [1], which tracks pharmaceutical patent information. This date applies to the initial formulation of semaglutide, and it's essential to note that generic versions can be introduced 6-12 months after the patent expires. Additionally, it's possible that Novo Nordisk may have secured extensions for specific use cases, such as pediatric or pediatric obesity treatments. However, these extensions would require separate patent filings.

As of now, Novo Nordisk has a strong patent portfolio around semaglutide, including the original semaglutide formulation and various formulations for injection and oral use. The company continues to expand its offerings, including a 2.5 mg oral version under development, which could potentially be patented separately.

Patent expiration does not necessarily impact the availability of branded semaglutide. However, it may influence market dynamics as generic manufacturers enter the market with their own versions of the medication.

[1] DrugPatentWatch.com - Semaglutide Patent Information

Sources:
1. DrugPatentWatch.com - Semaglutide Patent Information [https://www.drugpatentwatch.com/product/semaglutide]